182 related articles for article (PubMed ID: 25231690)
1. Sequential treatment with taxanes and novel anti-androgenic compounds in castration-resistant prostate cancer.
Esch L; Schulz WA; Albers P
Oncol Res Treat; 2014; 37(9):492-8. PubMed ID: 25231690
[TBL] [Abstract][Full Text] [Related]
2. Metastatic prostate cancer in 2015: The new and the old that is new again.
Graff JN; Beer TM
Nat Rev Clin Oncol; 2016 Feb; 13(2):73-4. PubMed ID: 26718107
[No Abstract] [Full Text] [Related]
3. Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity.
Schutz FA; Buzaid AC; Sartor O
Crit Rev Oncol Hematol; 2014 Sep; 91(3):248-56. PubMed ID: 24613528
[TBL] [Abstract][Full Text] [Related]
4. Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.
Saad F; Miller K
Urol Oncol; 2014 Feb; 32(2):70-9. PubMed ID: 23506965
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).
Sonpavde G; Wang CG; Galsky MD; Oh WK; Armstrong AJ
BJU Int; 2015 Jul; 116(1):17-29. PubMed ID: 25046451
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy in Prostate Cancer.
Hurwitz M
Curr Oncol Rep; 2015 Oct; 17(10):44. PubMed ID: 26216506
[TBL] [Abstract][Full Text] [Related]
8. Sequencing current therapies in the treatment of metastatic prostate cancer.
Valenca LB; Sweeney CJ; Pomerantz MM
Cancer Treat Rev; 2015 Apr; 41(4):332-40. PubMed ID: 25784591
[TBL] [Abstract][Full Text] [Related]
9. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
[TBL] [Abstract][Full Text] [Related]
10. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
[TBL] [Abstract][Full Text] [Related]
11. Castration-resistant prostate cancer: AUA Guideline.
Cookson MS; Roth BJ; Dahm P; Engstrom C; Freedland SJ; Hussain M; Lin DW; Lowrance WT; Murad MH; Oh WK; Penson DF; Kibel AS
J Urol; 2013 Aug; 190(2):429-38. PubMed ID: 23665272
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
Kluetz PG; Ning YM; Maher VE; Zhang L; Tang S; Ghosh D; Aziz R; Palmby T; Pfuma E; Zirkelbach JF; Mehrotra N; Tilley A; Sridhara R; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2013 Dec; 19(24):6650-6. PubMed ID: 24150234
[TBL] [Abstract][Full Text] [Related]
14. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J
Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
[TBL] [Abstract][Full Text] [Related]
15. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R
Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
[TBL] [Abstract][Full Text] [Related]
16. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
Mukherji D; Omlin A; Pezaro C; Shamseddine A; de Bono J
Cancer Metastasis Rev; 2014 Sep; 33(2-3):555-66. PubMed ID: 24452758
[TBL] [Abstract][Full Text] [Related]
17. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
18. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
Ecstein-Fraisse E; Su Z
Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
Derosa L; Galli L; Orlandi P; Fioravanti A; Di Desidero T; Fontana A; Antonuzzo A; Biasco E; Farnesi A; Marconcini R; Francia G; Danesi R; Falcone A; Bocci G
Cancer; 2014 Dec; 120(24):3923-31. PubMed ID: 25111199
[TBL] [Abstract][Full Text] [Related]
20. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
Heidenreich A; Bracarda S; Mason M; Ozen H; Sengelov L; Van Oort I; Papandreou C; Fossa S; Hitier S; Climent MA;
Eur J Cancer; 2014 Apr; 50(6):1090-9. PubMed ID: 24485664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
